Abstract: One example embodiment of the present invention relates to an implant with a coating or a cavity filling containing a nucleic acid, which i) can inhibit the expression of at least one representative of the Ras gene family by means of RNA interference; or ii) encodes for a nucleic acid that can inhibit the expression of at least one representative of the Ras gene family by means of RNA interference.

Abstract: The present invention relates to a biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus, the implant having a base body which is completely or partially composed of a biocorrodable metallic material, and the base body having a coating with a protective layer which is not biocorrodable. According to the invention, the implant has control elements which are configured in such a way that the protective layer, optionally in combination with the control elements, completely or partially encloses the base body so as to be impermeable to bodily medium, and the protective layer being to convertible to a form which is permeable to bodily medium as the result of a change in shape of the control elements which may be regulated and/or controlled by an external stimulus.

Abstract: One embodiment of the invention relates to a medical implant whose surface is completely or partially covered by a coating composed of at least one active substance or containing at least one active substance.

Abstract: An embodiment of the present invention relates to a balloon catheter, which has a drug-releasing coating and/or cavity filling on at least parts of the outwardly facing surface of the dilatable balloon, characterized in that the coating comprises a drug and a gelatin mixture, the gelatin components of the gelatin mixture comprising 10-90 wt. % high-bloom gelatin having a gel strength of?250 bloom and 90-10 wt. % medium-bloom gelatin having a gel strength of?50 to<250 bloom, the specifications in wt. % relating to the total weight of the gelatin components of the gelatin mixture.

Abstract: One embodiment of the present invention is an implant with an aptamer coating, wherein the aptamer has an activating effect on the ?v?3 integrin receptor, for improving the endothelial cell adhesion to the implant, a process for producing same, and uses thereof.

Abstract: One embodiment of the invention relates to an implant with a coating containing at least one active pharmaceutical substance. The inventive implant is characterized in that the coating is covered by a protective layer comprising or containing one or more materials from the group including shellac, vinylpyrrolidone-vinyl acetate copolymer, vinyl acetate-crotonic acid copolymer, vinyl acetate-vinyl propionate-crotonic acid terpolymer, methylvinyl ether-maleic anhydride copolymer, vinylpyrrolidone-dimethylaminoethyl acrylate copolymer, polyvinylpyrrolidone, polyvinyl acetate, polycrotonic acid, polyvinyl propionate, polymethylvinyl ether, polymaleic anhydride and polydimethylaminoethyl acrylate.

Abstract: An x-ray marker for medical implants made of a biocorrodible metallic material, wherein the x-ray marker composite includes 1-40 weight parts of a carrier matrix having a melting point greater than or equal to 43° C., which comprises 90 weight-percent or more at least one triglyceride; and 60-99 weight parts of a radiopaque marker component which is embedded in the carrier matrix.

Abstract: One embodiment of the invention concerns an implant with a basic body of biocorrodible, metallic implant material with an active coating and/or cavity filling.

Abstract: One embodiment of the invention concerns a medical implant with the basic body having an antioxidative substance.

Abstract: One embodiment of the invention relates to an implant having a basic body composed of a biocorrodible material and having an active coating or filling of a cavity, consisting of or containing the components a) at least one pharmaceutically active substance; and b) an ancillary substance for improving the permeability of the at least one pharmaceutically active substance.

Abstract: The present invention concerns medical products that release pharmaceutically active substances, the efficiency of which is increased as the result of a combination with an inhibitor of the transport protein P-glycoprotein.

Abstract: The invention relates to an implant having a base body consisting completely or partially of a biocorrodible metallic material, the material being such that it decomposes in an aqueous environment to yield an alkaline product and the base body has a coating comprising or containing a hydrogel, characterized in that the hydrogel has a reduced swelling capacity at an elevated pH.

Abstract: The invention relates to an implant having a base body, consisting completely or partially of a biocorrodible metallic material, such that it decomposes in an aqueous environment to form an alkaline product, and the base body has a coating or a cavity filling, comprising a polymer matrix and at least one drug embedded in the polymer matrix, characterized in that at least one polymer of the matrix and the at least one drug are coordinated so that the drug elution rate from the matrix is increased with an increase in pH.

Abstract: The present invention concerns an implant with a molecularly imprinted polymer coating, a process for its synthesis, a molecularly imprinted polymer, as well as a process for its synthesis and its use as well as a process for the treatment or prophylaxis of certain disease conditions by implantation of an implant in accordance with the invention according to the respective independent claims.

Abstract: The invention relates to a drug-loaded implant having a carrier body (10) and at least one drug for delivery into a delivery region. The drug is provided for chemotherapy and/or palliative treatment and can be released topically and/or regionally in a controlled manner at a predefinable rate and/or over a predefinable period of time in the intended active state of the implant.

Abstract: An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of ?, where ??80°. Also disclosed is a method for producing an implant and the use an implant to reduce the dose or concentration in administration of a concomitant systemic medication with one or more anticoagulant active ingredients before, during or after implantation of the implant in a human or animal body.

Abstract: A stent fixation system 3 for fixation of a stent, comprising two retaining areas 10 which are connected by a connecting area 12 to form a fixation tubing. The retaining areas 10 provide a retaining structure which is designed to hold at least one stent strut 2 of the stent in the undilated state, such that the stent struts 2 are no longer in one of the retaining areas 10, at least in the dilated state of the stent.

Abstract: An implant having a base body consisting entirely or in part of a biocorrodible metallic material wherein at least the parts of the base body made of the biocorrodible metallic material are covered with a corrosion-inhibiting coating. The coating comprises a primer layer of a first biodegradable polymer material comprising a poly(D,L-lactide) (PDLLA) with a degree of polymerization in the range of 5 to 20 and a protective layer of a second biodegradable polymer material comprising a diblock copolymer (PEG/PLGA) of polyethylene glycol (PEG) and poly(D,L-lactide-co-glycolide) (PLGA) applied to the primer layer.

Abstract: A stent having a base body of a bioinert metallic implant material wherein the base body is covered with an SiC coating. An external surface of the base body has a plurality of cavities which are filled with an antiproliferative active ingredient, A luminal surface of the base body has a coating which contains or comprises attractors for endothelial cells.

Abstract: A stent having a coating comprising either L-3,4-dihydroxyphenylalanine (L-DOPA) or a derivative of L-3,4-dihydroxyphenylalanine (L-DOPA), the foregoing obtained by either ionic or covalent bonding of a pharmaceutical active ingredient to either the amino or the acid function of L-3,4-dihydroxyphenylalanine (L-DOPA).